Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period.
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, abrupt discontinuation of GLP-1 RAs during the perioperative period may worsen glycemic control, increase insulin requirements, and negate established cardiometabolic and renal benefits, potentially introducing additional perioperative risk [7].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some professional bodies recommend considering withholding GLP‐1 RAs before surgery but emphasise that there is limited evidence available about the effectiveness of this strategy [16, 21, 22, 23].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternative strategies, including changing pre‐operative fasting guidance, using prokinetic drugs and implementing routine point‐of‐care ultrasound to mitigate risk, have been suggested, but their effectiveness also remains uncertain [21, 26].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the initial guidance for preoperative management of GLP-1 RAs advocated a conservative strategy, recommending temporary discontinuation for safety considerations.”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently, multi‐societal consensus statements across the UK, USA and Australia support a shared decision‐making approach for minimising risk among patients using GLP‐1 RAs [18, 21, 22].”
From Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis (2025) · cites this paper as [21]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“Further, GLP-1RAs induce common side effects of nausea, vomiting, abdominal pain, and constipation, which may complicate the diagnosis and treatment of pre-and post-operative disease states that share these symptoms [10].”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety [1, 2].”
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285 · cited 1×
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the care of patients with metabolic disease due in part to the agonists’ unique combination of effects, including decreasing hyperglycemia and enhancement of satiety [1, 2].”
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259 · cited 1×
“…can be utilized in patients when there is concern for delayed gastric emptying based on clinical symptom review as described in Recommendation 1a [5, 11, 15]. b) When clinical concern for retained gastric contents exists on the day of the procedure, point-of-care gastric ultrasound could be used…”
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report
Klein, S. R., & Hobai, I. A. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02440-3 · Cited by 207
Gulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153
Hashash, J. G., Thompson, C. C., & Wang, A. Y. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.002 · Cited by 140 · cited 3×
“…be utilized in patients when there is concern for delayed gastric emptying based on clinical symptom review as described in Recommendation 1a [5, 11, 15]. b) When clinical concern for retained gastric contents exists on the day of the procedure, point-of-care gastric ultrasound could be used to…”
Self-citationSherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132 · cited 1×
“An increasing safety concern has developed amongst providers regarding the perioperative use of GLP-1RA due to delayed gastric emptying and subsequent residual gastric contents on the day of the procedure despite traditional fasting [4–6].”
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“85,89 Further prospective studies are needed to clarify perioperative risks associated with GLP-1 RA use and inform individualized management.”
16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s016 · Cited by 80
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“…contents and risks for aspiration pneumonia have led to multiple guidelines and recommendations surrounding perioperative assessment and individualized recommendations surrounding continuation or cessation of GLP-1 medicines in people undergoing elective endoscopy or surgical procedures 78 .”
Castrillon, J., Rele, S., Sumithran, P., Hii, M., Thuraisingam, S., Spelman, T., Phan, T., Choong, P., Dowsey, M., & Shadbolt, C. (2025) · Anaesthesia · doi:10.1111/anae.16601 · Cited by 65
“Alternative strategies, including changing pre-operative fasting guidance, using prokinetic drugs and implementing routine point-of-care ultrasound to mitigate risk, have been suggested, but their effectiveness also remains uncertain [21, 26].”
InfluentialJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“Multi-society consensus guidelines have, in general, recommended an individualized approach toward the decision to withhold GLP-1RA therapy (46).”
Metadata
- Authors
- Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S., Joshi, G. P., LaMasters, T., & Representing the American Gastroenterological Association, A. S. F. M. A. B. S.
- Affiliations
- Medical College of Wisconsin (US)
- University of Virginia (US)
- The University of Texas Southwestern Medical Center (US)
- University of Michigan (US)
- Weill Cornell Medicine (US)
- Cleveland Clinic (US)
- Mayo Clinic (US)
- Tulane University (US)
- University of Iowa (US)
- Corresponding author
- Kindel, Tammy L.
- ORCID
- Venue
- Surgical Endoscopy
- Published
- 2024-10-29
- Volume
- 39
- Issue
- 1
- Pages
- 180-183
- ISSN
- 0930-2794 (ISSN-L)
- 1432-2218
- PMC
- PMC11666732
- OpenAlex
- W4403162749
- Cited by
- 98
- References
- 13
- Citations by year
- 2026: 57 · 2025: 40 · 2024: 1
- FWCI
- 32.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Surgical Endoscopy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Society of American Gastrointestinal and Endoscopic Surgeons
- American Gastroenterological Association
- American Society for Metabolic and Bariatric Surgery
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac, Anesthesia and Surgical Outcomes
- Keywords
- GLP-1 receptor agonists, perioperative care, surgical patients, diabetes mellitus, drug safety, clinical guidelines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. https://app.cochat.ai/papers/10.1007/s00464-024-11263-2
- The paper
- Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S., Joshi, G. P., LaMasters, T., & Representing the American Gastroenterological Association, A. S. F. M. A. B. S. (2025). Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgical Endoscopy. https://doi.org/10.1007/s00464-024-11263-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.